A 24‐Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3 mg/24 h Versus 4.6 mg/24 h in Severe Alzheimer's Dementia

AIMS: The 24‐week, prospective, randomized, double‐blind ACTION study investigated the efficacy, safety, and tolerability of 13.3 versus 4.6 mg/24 h rivastigmine patch in patients with severe Alzheimer's disease (AD). METHODS: Patients had probable AD and Mini–Mental State Examination scores ≥3...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:CNS Neurosci Ther
Egile Nagusiak: Farlow, Martin R., Grossberg, George T., Sadowsky, Carl H., Meng, Xiangyi, Somogyi, Monique
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2013
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4233957/
https://ncbi.nlm.nih.gov/pubmed/23924050
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cns.12158
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak